A prodrug approach was adopted to minimize exposure of body tissues to free oxaliplatin. A variety of oxaliplatin prodrug derivatives were designed to release free oxaliplatin in a site-directed manner within tumour tissue. They were tested for efficacy in cellular and xenograft models. One class of derivatives exhibited remarkable effects on survival of tumorigenic mice relative to free oxaliplatin.